Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee
Others

Rona Therapeutics siRNA RN5681 Submitted to Australian Ethics Committee

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
CompanyDrug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
CompanyDrug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
CompanyDrug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
CompanyDrug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
CompanyDrug

Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study
CompanyDrug

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B
CompanyDeals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

China Mandates Specialty Departments in Primary Care by 2030
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
CompanyDeals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch
Hospital

Hainan Opens First Wholly Foreign-Owned Hospital Ahead of Free Trade Port Launch

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors
CompanyDrug

Hutchmed’s HMPL-A251 ATTC Dosed in Global Phase 1 for HER2 Tumors